What is the Role of Third Generation Regimens for Initial Therapy of Non-Hodgkin's Lymphomas?

References

• McKelvey E. M., Gottlieb J. A., Wilson H. E., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Gaynor E. R., Ultmann J. E., Golomb H. M., et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): A 10-year experience in a single institution. J. Clin. Oncol. 1985; 3: 1596–1604
   PubMed Web of Science ®Google Scholar
• Lawrence J., Coleman M., Allen S. L., et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with six-drug COP-BLAM regimen. Ann. Intern. Med. 1982; 97: 190–195
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Weisenburger D. D., Hutchins M., et al. Chemotherapy for diffuse large-cell lymphoma: Rapidly responding patients have more durable remission. J. Clin. Oncol. 1986; 4: 160–164
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Yeap B. Y., Harrington D. P., et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J. Clin. Oncol. 1990; 8: 84–93
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. M. Updated clinical experience with MACOP-B. Sem. Hem. 1987; 24: 26–34
   PubMed Web of Science ®Google Scholar
• Longo D. L., DeVita V. T., Duffey P. L., et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J. Clin. Oncol. 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Cheson B. D. Interpretation of clinical trials in diffuse large-cell lymphoma. J. Clin. Oncol. 1988; 6: 1335–1347
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Glick J. H., et al. Randomized Phase III comparison of CHOP vs m-BACOD in diffuse large cell (DH) and diffuse mixed (DM) lymphoma: Equivalent complete response (CR) rates and time to treatment failure (TTF) but greater toxicity with m-BACOD (abstr). Proc. Am. Soc. Clin. Oncol. 1989; 8: 255a
   Google Scholar
• Cooper I. A., Ding J. C., Matthews J. P., et al. A randomized comparison of MACOP-B and CHOP in in-termediate grade non-Hodgkin's lymphoma. Proc. ASCO 1991; 10: 271a
   Google Scholar
• Garcia-Conde J., Vinolas N., Estape J. ProMACE-CytaBOM vs CHOP in the treatment of unfavorable lymphomas: A randomized trial. Blood 1991; 78: 127a
   Google Scholar
• Tura S., Zinzani P. L., Mazza P., et al. F-MACHOP versus MACOP-B in the treatment of high grade malignant non-Hodgkin's lymphomas. Blood 1991; 78: 109a
   Google Scholar
• Gherlinzoni F., Guglielmi C., Mazza P., et al. Phase III comparative trial (m-BACOD vs m-BNCOD) in the treatment of Stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. Sem. Oncol. 1990; 17: 3–9
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E., Dahlberg S., et al. A Phase HI comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Intergroup 0067), the national high priority lymphoma study. Proc. ASCO 1992; 11: 315a
   Google Scholar
• Shipp M. A., Harrington Anderson J., et al. Development of a predictive model for aggressive lymphoma: The international NHL Prognostic factors project. Proc. ASCO 1992; 11: 319a
   Google Scholar
• National Cancer Institute, Division of Cancer Prevention and Control, US Department of Health and Human Services. Public Health Service, National Institutes of Health, Bethesda 1988, 1987 Annual Cancer Statistics Review
   Google Scholar
• Vose J. M., Armitage J. O., Weisenburger D. D., et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Chastang C., Herrera A., et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am. J. Med. 1987; 83: 1075–1079
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Klimo P., Connors J. M. Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J. Clin. Oncol. 1991; 9: 741–747
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Errante D., et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J. Clin. Oncol. 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• Gill P. S., Levine A. M., Krailo M., et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J. Clin. Oncol. 1987; 5: 1322–1328
   PubMed Web of Science ®Google Scholar
• Bermudez M. A., Grant K. M., Rodvien R., et al. Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: indications for intensive chemotherapy. Am. J. Med. 1989; 86: 71–76
   PubMed Web of Science ®Google Scholar
• Miller T. P., Jones S. E. Initial chemotherapy for clinicall localized lymphomas of unfavorable histology. Blood 1983; 62: 413–418
   PubMed Web of Science ®Google Scholar
• Connors J. M., Klimo P., Fairey F. N., et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann. Intern. Med. 1987; 107: 25–30
   PubMed Web of Science ®Google Scholar
• Picozzi V. J., Coleman C. N. Lymphoblastic lymphoma. Sem. Oncol. 1990; 17: 96–103
   PubMed Web of Science ®Google Scholar
• Anderson J. R., Wilson J. F., Jenkin E. T., et al. Childhood non-Hodgkin's lymphoma: The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2L2). N. Engl. J. Med. 1983; 308: 559–565
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Kekker A. W., de Gast G. C., et al. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J. Clin. Oncol. 1992; 10: 644–646
   PubMed Web of Science ®Google Scholar